MBrace Therapeutics’ Post

Preparation is the key to success! 🚀 Yesterday's webinar with Alexander Natz and Matias Olsen was full of relevant insights on the JCA process. 👇👇👇 Thank you both for your clear presentation. One key point that you both mentioned and that is critical, is "PREPARATION" Start considering early enough in the process, the data that must be collected, potential comparators, the HTA path which needs to be followed, the need or not for Scientific consultations. Based on my experience, preparing in advance can significantly increase the chances of reimbursement success across different countries. The HEOR/MAx strategy should be considered as early as Phase I, if not even before. We need to invest in thorough preparation to set the product/intervention up for success! 🌟

Not long to go until #ESMO24! Really excited to be attending along with our talented team of Inizio experts. We will be at booth 431e, ready to answer all your oncology questions. In the meantime, check out our new blog, where Heidi Bell, Group Growth Director, Inizio Evoke Europe, discusses The invisible epidemic of bias in oncology. #ESMO24 #Oncology #ReimagineHealth #OncologyTreatments

Bridging the gap between in vitro and in vivo data just became simpler. We're proud to introduce you to our In vivo Hollow Fiber Platform! Click on the link below to learn more --> https://hubs.ly/Q02LVy0d0 #cancerresearch #invivomodelfortumor #oncologydrugdevelopment

If we've talked preclinical drug discovery, we've talked about the power of screening with the Hollow Fiber Assay (HFA). The literature is a great place to start, but when it comes to your first lead/target validation efficacy study, nothing beats choosing your model and dosing regimen based on empirical data collected in our in vivo HFA screen. Let's chat! #oncologyresearch #drugdevelopment #researchtools

🔔Upcoming Webinar🔔 “Oncology Breakthroughs: Emerging Trends and Pioneering Research.” Dive into the latest developments in #oncology treatments and research, the role of biosafety and Institutional Biosafety Committee (IBC) oversight, Institutional Review Board (IRB) considerations in pioneering research, and WCG’s IBC and IRB impact on revolutionary treatments.  Secure your spot and register now at https://lnkd.in/eanP4g8c #WCG #webinar #ethicalreview #IRB #IBC #oncologyresearch

Check out this post! I had the pleasure of meeting Yuan Tian at a Data Science Meetup in Columbus a while ago. This is a very interesting topic worth checking out!

Please check this out! In case you would like to read the full infographic including all "10 Strides Forward in Cancer": https://bit.ly/3uBvFQL

Join Regina Hargrove at #SROA2024 today at 3:45pm for "Hypofractionation: The Impacts of Clinical Advancements". This presentation will discuss the interplay between reimbursement dynamics, technological innovations, and clinical practice. This presentation aims to provide valuable insights for radiation oncology administrators grappling with the complexities of hypofractionation. Questions for our experts? Connect with them here or contact us at info@radiationbusiness.com.

Flow is absolutely critical in #cancertherapy development. Translational Drug Development (TD2) can help from the #benchtotheclinic. #preclinicalresearch #flowcytometry #clinicalresearch

Today marks a significant milestone for Black Diamond as we unveil initial Phase 2 results for BDTX-1535 in patients with recurrent #EGFR-mutated #NSCLC. Results show a 42% preliminary ORR in a well-defined patient population, with encouraging durability of responses. The tolerability profile of BDTX-1535 remains favorable. We have selected the 200mg dose for pivotal development, and look forward to disclosing initial Phase 2 data of BDTX-1535 in the frontline setting in the first quarter of 2025.   Read more: https://lnkd.in/e-GPYbm8 #biotech #oncology #healthcare #innovation